Juan Pablo Horcajada, MD. is Head of the Department of Infectious Diseases and General Coordinator of the COVID-19 Service at the Hospital del Mar, Barcelona. His interests are nosocomial infection prevention, surveillance and control and antimicrobial therapy. He has worked extensively in the area of multidrug resistant microorganisms, nosocomial infectious outbreaks, urinary tract infections, antibiotic stewardship, and pharmacokinetics of antimicrobial drugs.
Scientist: Juan Pablo Horcajada
The key role of antivirals in COVID-19 treatment (remdesivir)
A few weeks after the SARS-CoV-2 was identified by Chinese researchers as the cause of ‘COVID-19’, an antiviral called remdesivir, originally used during the 2014 Ebola outbreak, came into play as the first available option to treat patients with coronavirus disease 2019 (COVID-19). Even if the approval process for remdesivir caused some controversy, experts consider the combined use of antivirals and other drugs a promising solution for treatment of Covid-19.
A scientist’s opinion : Interview with Dr Juan Pablo Horcajada about covid-19 treatment
Interview with Juan Pablo Horcajada, MD. is Head of the Department of Infectious Diseases and General Coordinator of the COVID-19 Service at the Hospital del Mar, Barcelona. Remdesivir is the first drug approved by the EMA to be used as part of the treatment of COVID-19 patients. How’s the use of this antiviral in your ...